OCGN
NASDAQ · Biotechnology
Ocugen Inc
$1.39
+0.01 (+0.72%)
Open$1.37
Previous Close$1.38
Day High$1.41
Day Low$1.37
52W High$2.73
52W Low$0.90
Volume—
Avg Volume7.43M
Market Cap419.77M
P/E Ratio—
EPS$-0.18
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+2,056.1% upside
Current
$1.39
$1.39
Target
$29.97
$29.97
$22.68
$29.97 avg
$39.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.82M | 214.85M | 205.76M |
| Net Income | -74,115,128 | -16,849,465 | -19,542,916 |
| Profit Margin | -1,537.4% | -7.8% | -9.5% |
| EBITDA | -66,113,318 | -26,350,714 | -23,624,019 |
| Free Cash Flow | — | -15,177,197 | -13,829,123 |
| Rev Growth | — | +3.8% | +8.3% |
| Debt/Equity | 0.97 | 0.42 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |